Figure 2. Influence of Bcl11b level on apoptosis and cell survival.

(A) Mock- and BCL11B-transduced cells were treated or not with etoposide (10 µM) and camptothecin (2 µM). The influence of the treatment on cell viability was evaluated 6h later using a allophycocyanin-labeled Annexin-V binding assay and subsequent FACS analysis. The data represent one of at least three independent experiments. (B) The 6 hours etoposide and camptothecin treatments followed by the Annexin-V binding assay were performed using increasing concentrations of the radiomimetic drugs. (C) Mock- or BCL11B-transduced Jurkat and huT-78 cells were pulse-treated with 50 µM etoposide. The survival rate was determined by live cell counting performed every 48h after etoposide removal. (D) The cells with endogenous and elevated BCL11B expression were incubated with increasing amounts of the recombinant tumor necrosis factor related apoptosis inducing ligand (rTRAIL) for 6h. The procedure was followed by FACS-based Annexin-V binding detection. The data shown in B, C and D represent mean values ± standard deviations (SD) obtained from at least three independent experiments. Statistical significance was calculated using t-Student test. *p<0.01.